Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 2 of 5 (40%) have an AI response strategy ready • 5 patents granted in the last 365 days
Scholar Rock Inc. currently manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, indicating a diverse range of review for the company's patent applications. The prosecution also spans 3 distinct art units, showing that the company's filings are being evaluated across multiple technical specialties. Amber Kathleen Faust is the busiest examiner, overseeing 1 pending office action.
The distribution of 4 pending office actions across 4 distinct examiners suggests that no single individual controls the majority of the company's current prosecution. Amber Kathleen Faust's management of 1 pending office action represents a single component of the active portfolio. The involvement of 3 distinct art units within the Biotechnology & Pharmaceuticals sector implies a broad technical scope for the company's pending matters. This arrangement requires the company to address the specific requirements of 4 distinct examiners across different examination groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
| SULLIVAN, DENNIS JOHN | 1 | 57.6% | +48.0% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.7% | +47.4% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17248700 | USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES | SULLIVAN, STEPHANIE LAUREN | 30d |
| 18283904 | TGF-BETA INHIBITORS AND USE THEREOF | JOHNSON, TIRONE DEREK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17248700 | USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES | SULLIVAN, STEPHANIE LAUREN | 30d |
| 18578341 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
| 18363435 | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF | SULLIVAN, DENNIS JOHN | — |
| 18250489 | USE OF ANTI-PRO/LATENT MYOSTATIN ANTIBODY FOR TREATING SPINAL MUSCULAR ATROPHY | DONOGHUE, BRITTNEY ERIN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1643 | 1 |
| 1642 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578341 | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF | FAUST, AMBER KATHLEEN | 1643 | §102§103§112DP | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18283904 | TGF-BETA INHIBITORS AND USE THEREOF | JOHNSON, TIRONE DEREK | 1675 | §103§112 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18363435 | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF | SULLIVAN, DENNIS JOHN | 1642 | §112 | Non-Final OA | — | AI Ready | Aug 01, 2023 |
| 18250489 | USE OF ANTI-PRO/LATENT MYOSTATIN ANTIBODY FOR TREATING SPINAL MUSCULAR ATROPHY | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112DP | Non-Final OA | — | Pending | Apr 25, 2023 |
| 17248700 | USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES | SULLIVAN, STEPHANIE LAUREN | 1635 | §102§103Other | Final Rejection | 30d | AI Ready | Feb 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialScholar Rock Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Amber Kathleen Faust has the most, with 1 of Scholar Rock Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
